Physicians' Academy for Cardiovascular Education

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona

Video navigation menu

  • Another milestone on the roadmap towards the acceptance of the LDL-hypothesis 0:24
  • Effects of treatement with PCSK9 1:44
  • LDL-c lowering by PCSK9 inhibition in HoFH patients and the effect on apheresis treatment 5:29
  • Real-world experience with PCSK9 inhibition in HeFH patients 7:07
  • Other insights gained from the PCSK9 antibody clinical trial programs 9:11
  • Other approaches to inhibit PCSK9 include siRNAs, vaccins, adnectins and small molecules 12:06

Educational information

The educational objectives of the symposium were to:

Disclosures

Kees Hovingh, MD is an internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK. Hovingh is co-chair of the department of internal medicine at the AMC and in his role as head of the clinical trial unit involved in a large number of clinical trials, mainly focused on novel therapies to combat (the consequences of) dyslipidemia.

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Funding

This symposium was supported by unrestricted educational grant provided by Amgen and Sanofi-Regeneron

The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-CME.

Prof Hovingh = Biography and keyslides View and download slides